Parallax Volatility Advisers, L.P. Apellis Pharmaceuticals, Inc. Put Options Transaction History

Parallax Volatility Advisers, L.P.

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2023 Feb 14, 2024	BUY	$37.14 - $64.82 $3,714 - $6,481	100 New	100 $5,000
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $3.48 Million - $5 Million	-74,600 Reduced 99.47%	400 $26,000
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $3.24 Million - $4.58 Million	75,000 New	75,000 $3.88 Million
Q4 2021 Feb 14, 2022	SELL	$30.74 - $49.16 $1.05 Million - $1.69 Million	-34,300 Reduced 52.29%	31,300 $1.48 Million
Q3 2021 Nov 15, 2021	SELL	$31.4 - $69.84 $1.77 Million - $3.94 Million	-56,400 Reduced 46.23%	65,600 $2.16 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $3.99 Million - $6.33 Million	97,500 Added 397.96%	122,000 $7.71 Million
Q1 2020 May 15, 2020	BUY	$17.91 - $44.33 $214,920 - $531,960	12,000 Added 96.0%	24,500 $656,000
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $276,250 - $385,000	12,500 New	12,500 $383,000

310

113M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.29B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.